This trial is testing a novel intervention, PAL2, to see if it is more effective than usual care in reducing blood pressure and preventing stage 1 hypertension in 500 black adults with elevated blood pressure. The intervention is being delivered in deprived neighborhoods by community health workers using a personalized, adaptable approach. The trial will also assess the reach, adoption, sustainability and cost-effectiveness of LEAP-HTN at 12 and 24 months.
- High Blood Pressure
- Cardiovascular Disease
1 Primary · 3 Secondary · Reporting Duration: 24 months
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
500 Total Participants · 2 Treatment Groups
Primary Treatment: PAL2 · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
How many prior treatments have patients received?
Frequently Asked Questions
Is it still possible for individuals to take part in this experiment?
"Affirmative. According to information on clinicaltrials.gov, this medical trial is currently enrolling patients - the study was initially posted in August 8th 2022 and its most recent update happened at September 29th of the same year. 500 participants are required for this experiment located within a single site." - Anonymous Online Contributor
How many participants are recruited for this trial?
"Affirmative. Current details on clinicaltrials.gov confirms this research is in the process of recruitment, having been launched on August 8th 2022 and edited most recently on September 29th 2022. The investigation requires 500 volunteers at a single medical facility to participate." - Anonymous Online Contributor